DrugMapper
  • Browse
    • Therapeutic Area
      • CANCER (51)
      • CARDIOVASCULAR (45)
      • DENTISTRY (2)
      • DERMATOLOGY (31)
      • DIABETES DRUGS & ENDOCRINOLOGY (61)
      • EMERGENCY MEDICINE (3)
      • ENT (5)
      • EYE (23)
      • GASTROINTESTINAL (29)
      • HEMATOLOGY (23)
      • MUSCULOSKELETAL (28)
      • NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
      • PEDIATRICS (27)
      • PHARMACOLOGY (8)
      • PREGNANCY AND GYNECOLOGY (30)
      • RESPIRATORY (42)
      • RHEUMATOLOGY (19)
      • OTHER (1482)
    • Therapeutic Indication
    • Adverse Reaction (System Organ Classification)
    • Mechanism of Action
    • Primary Target
    • Target Level
      • Level 1
      • Level 2
      • Level 3
      • Level 4
      • Level 5
      • Level 6
    • Active Pharmaceutical Ingredients (APIs)
    • Small Molecules
    • ProDrugs
    • Antibodies
    • CNS drugs
    • Metabolites
  • Search
      Therapeutic Indication Adverse Reaction (System Organ Classification)
      Mechanism of Action Target Sequence
      Chemical Structure Physicochemical Properties
  • Analyze

      Networks

    • Chemical Similarity
    • Scaffold Similarity
    • KNIME workflow
  • Downloads
      Web services Bulk Downloads
  • About
      DrugMapper FAQs Data Sources Contact Us

DENENICOKIN

Search structure
Synonyms:
BMS-982470
DENENICOKINA
DENENICOKINE
HUMAN INTERLEUKIN-21
IL-21
IL21, HUMAN
IL-21 RECOMBINANT
INTERLEUKIN-21
RECOMBINANT HUMAN IL-21
RECOMBINANT HUMAN IL-21 (E. COLI)
RECOMBINANT HUMAN INTERLEUKIN 21
RIL-21
RIL-21; RECOMBINANT HUMAN INTERLEUKIN 21
Status: Phase 2
Entry Type: Protein
Molecule Category: UNKNOWN
UNII: A4LY1V9F0H

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 2 D009369 ClinicalTrials
Carcinoma, Renal Cell 2 D002292 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Ovarian Neoplasms 2 D010051 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Lymphoma, Non-Hodgkin 1 D008228 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL2107855
FDA SRS A4LY1V9F0H
CONTENTS
  • Structure
  • Indications
  • Cross References
×
70